CD274 and non-small cell lung carcinoma: Although immune checkpoint blockade with monoclonal antibodies has recently emerged as a new therapeutic strategy in several malignancies, the role of PD-L1 expression and TIL density in NSCLC patients receiving adjuvant chemotherapy remains largely unknown.